Physician profile
Eric W Barnes
NPI 1225193022
$562.82
in general payments reported to CMS, 2019-2025
14 companies · $43.04 in 2025
The $43.04 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $239 · 2021: $59.09 · 2024: $18.44 · 2025: $43.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $61.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $61.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $115.51 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $107.94 | 2019-2020 | |
| Amgen INC. | $60.13 | 2019-2025 | Repatha |
| Akebia Therapeutics INC | $45.51 | 2019-2020 | |
| Vifor Pharma, INC. | $44.89 | 2019-2021 | |
| Daiichi Sankyo INC. | $41.18 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $23.45 | 2021 | |
| Lemaitre Vascular, INC. | $23.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $23.05 | 2020 | |
| Philips North America LLC | $18.44 | 2024 | (Ck7) Extended Holter |
| Fresenius USA Marketing, INC. | $17.28 | 2020 | |
| Merck Sharp & Dohme LLC | $17.05 | 2025 | Keytruda |
| Alexion Pharmaceuticals, INC. | $14.11 | 2019 | |
| Horizon Therapeutics Plc | $11.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.